Recruiting · registry status

Comparing medicines for daytime sleepiness

This study compares modafinil and methylphenidate for excessive sleepiness in Parkinson's.

Testing a treatment or activity · Study reference: IRCT20220623055257N1

Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓

This registry record was last updated over six months ago, or its update date is missing. Recruitment may have changed. Confirm with the team before making plans.

Open the official registry record ↗

Follow this study

Looking for volunteers

Start (reported date): 2022-08-23

Planned dates can move. A study finishing does not tell us when a paper will be published.

No results summary has been confirmed in the registry records we imported. See connected papers below; we keep checking after recruitment ends.

Changes we have recorded

2026-10-11 — recruiting

These are dates we observed a change, not necessarily the dates it happened.

Papers connected to this study

No connected paper has been found yet. The tracker checks the growing library for study identifiers and registry-linked publications.

Who can join?

Age range not listed · Ask the team who can join

These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.

Read all the rules for taking part

Sex eligibility reported by registry: both

Inclusion criteria: patients who have Parkinson disease diagnosis of excessive daytime sleepiness(EDS) by neurologist not having sensitivity to Modafinil or Methylphenidate Individual consent to participate in the study Exclusion criteria: Dissatisfaction of the patient to continue participating in the study history of head trauma diagnosis of other neurological disease such as Dementia thyroid disorder history of CVA drug abuser kidney or liver failure heart disease History of a psychiatric illness being treated with psychiatric medication Taking hypnotics being illiterate

Full study name & original research details

Official study title

comparison of the effectiveness of Modafinil and methylphenidate in treatment of excessive daytime sleepiness in patients with Parkinson disease

Original description

Intervention: Intervention 1: Intervention group: 30 patients with Parkinson's disease who are treated with medafinil at a dose of 200 mg daily for 8 weeks to treat daily drowsiness. Intervention 2: Intervention group: 30 patients with Parkinson's disease who are treated with methylphenidate at a dose of 10 mg daily for 8 weeks to treat daily drowsiness. Primary outcome: Daily sleepiness in patients with Parkinson's. Timepoint: Beginning of study and 8 weeks later. Method of measurement: Epworth Questionnaire.

Conditions reported: Daily-time sleepiness in patients with Parkinson's. Parkinson's disease

Registry records for this study

Records are joined using registration identifiers. Titles alone do not establish that two studies are the same.

IRCT · IRCT20220623055257N1 ↗ — Recruiting; WHO ICTRP processed 2022-08-29; checked 2026-10-14

Study type: Interventional
Interventions: Intervention 1: Intervention group: 30 patients with Parkinson's disease who are treated with medafinil at a dose of 200 mg daily for 8 weeks to treat daily drowsiness. Intervention 2: Intervention group: 30 patients with Parkinson's disease who are treated with methylphenidate at a dose of 10 mg daily for 8 weeks to treat daily drowsiness.
Phases: 3
Sponsor: Esfahan University of Medical Sciences
Start date reported by registry: 2022-08-23 (reported)

Registry updated: Not reported · Status last verified by the registry submitter: Not reported

Registry records retrieved 2026-10-14 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.

Contact the research team

Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.

Farzaneh Habibi · +98 31 3792 3071 · fh1390i@yahoo.com

Study locations

Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.

Facility not reported

Iran (Islamic Republic of)

Status not reported

The original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.